Images List Premium Download Classic

Steoporosis

Steoporosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Polypeptides derived from calcitonin receptors and methods of use
The Research Foundation For The State University New York
July 06, 2017 - N°20170190760

The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain ...
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4...
Pfizer Inc.
July 06, 2017 - N°20170190663

Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for ...
Solid oral formulation of fenretinide
Laurent Pharmaceuticals
July 06, 2017 - N°20170189356

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited ...
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Llp2a-bisphosphonate conjugates for osteoporosis treatment
The Regents Of The University Of California
June 22, 2017 - N°20170174722

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e. G. Llp2a, conjugated with a bisphosphonate drug, e. G. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal ...
Protease inhibitors
The Regents Of The University Of California
June 15, 2017 - N°20170166538

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases:
Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
Inflectis Bioscience
June 01, 2017 - N°20170151196

The present invention relates to novel uses of a compound of formula (i), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the ppp1r15a pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, ...
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Triphenylethylene compounds and uses thereof
Inflectis Bioscience
May 25, 2017 - N°20170144975

Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.
Calcitonin mimetics for treating diseases and disorders
Inflectis Bioscience
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
Compositions and methods for the diagnosis and treatment of bone fractures and disorders
Universität Für Bodenkultur Wien
May 11, 2017 - N°20170130268

The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected micro rnas in samples of patients are detected and wherein an increase or decrease of said level compared to the level of healthy individuals is indicative of the disorder.
Method for non surgical repair of vertebral compression fractures
Cedars-sinai Medical Center
May 04, 2017 - N°20170119823

Described herein are methods and compositions using pth and mesenchymal stem cells (mscs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both pth and mscs leads to increased homing of mscs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and ...
Calcium carbonate composition for ameliorating, preventing and treating osteoporosis, and manufacturing method therefor
Medience Co., Ltd.
May 04, 2017 - N°20170119815

The present invention relates to a calcium carbonate composition for ameliorating, preventing and treating osteoporosis, and a manufacturing method therefor. More specifically, the present invention relates to a calcium carbonate composition for alleviating, preventing and treating osteoporosis, the composition comprising calcium, magnesium and zinc, and having calcium carbonate microparticles formed by the supply of carbon dioxide gas. The present invention ...
Therapeutic agents for reducing parathyroid hormone levels
Kai Pharmaceuticals, Inc.
April 27, 2017 - N°20170114095

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, x1-x2-x3-x4-x5-x6-x7, wherein the x1 subunit comprises a thiol-containing moiety and the distribution of charge on the x2-x7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, ...
Urea compounds and their use as enzyme inhibitors
Kai Pharmaceuticals, Inc.
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of peptidic drugs for osteoporosis treatment and bone regeneration
Universidad Nacional Autonoma De Mexico
March 30, 2017 - N°20170088584

The present invention provides osteogenic peptides derived from the cementum-derived attachment protein (hacd1/cap) and another derived from the cementum protein 1 (cemp1) and pharmaceutical compositions of these peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increase bone mineral density in an osteoporotic model and without in vivo side effects, demonstrating clinical effectiveness in the prevention and ...
Furo[3,4-b]pyran compounds and pharmaceutical uses
Victoria Link Limited
March 30, 2017 - N°20170087124

Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.
Peptides for preventing or treating bone diseases and use thereof
Kyungpook National University Industry - Academic Cooperation Foundation
March 23, 2017 - N°20170081367

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or ...
Novel peptides for preventing or treating bone diseases and use thereof
Kyungpook National University Industry - Academic Cooperation Foundation
March 23, 2017 - N°20170081366

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or ...
Compositions and methods for treatment of osteoporosis and other indications
Transdermal Biotechnology, Inc.
March 23, 2017 - N°20170080016

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles ...
Selective elimination of erosive cells
Novo Nordisk A/s
March 16, 2017 - N°20170073417

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-nkg2a antibody.
Compositions and methods for controlled localized delivery of bone forming therapeutic agents
University Of Rochester
March 16, 2017 - N°20170072062

The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic ...
Use of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation ...
University Of Rochester
March 16, 2017 - N°20170071977

Through the use of a combination of naturally occurring substances, application of mechanical energy by way of exercise, and application of a pulsed electromagnetic field (pemf), new bone formation at lines of stress can be promoted. This bone forming activity is useful in the treatment and prevention of osteoporosis. The naturally occurring substances consist of organic sulphur, antioxidants, and amino ...
Loading